TABLE 6.

Levels of total cholesterol, HDL, LDL, and triglycerides based on visits (PP Set).

Parameters	Treatment	Test		Placebo		p-value
		No.	Mean ± SD	No.	Mean ± SD
Total cholesterol (mg/dl)	Baseline	37	197.30 ± 41.29	43	189.65 ± 39.34	0.3995 a
	6 weeks	37	189.05 ± 37.49	43	188.40 ± 35.82
	Change from baseline	37	-8.24 ± 28.27	43	-1.26 ± 23.24	0.1765 b
	p-value		0.0929 d		0.7248 c
	12 weeks	37	196.57 ± 44.39	43	186.88 ± 34.66
	Change from baseline	37	-0.73 ± 30.29	43	-2.77 ± 22.25	0.7303 a
	p-value c		0.8843		0.4194
HDL (mg/dl)	Baseline	37	53.43 ± 15.12	43	56.02 ± 13.20	0.1843 b
	6 weeks	37	51.76 ± 12.14	43	55.35 ± 14.05
	Change from baseline	37	-1.68 ± 9.04	43	-0.67 ± 7.22	0.5836 a
	p-value c		0.2672		0.5435
	12 weeks	37	53.62 ± 12.96	43	56.02 ± 12.52
	Change from baseline	37	0.19 ± 8.88	43	0.00 ± 9.34	0.9266 a
	p-value c		0.8976		1.0000
LDL (mg/dl)	Baseline	37	114.95 ± 37.88	43	113.40 ± 36.26	0.8523 a
	6 weeks	37	112.86 ± 32.86	43	110.79 ± 32.27
	Change from baseline	37	-2.08 ± 23.37	43	-2.60 ± 24.47	0.9227 a
	p-value c		0.5914		0.4891
	12 weeks	37	116.30 ± 32.40	43	110.30 ± 33.23
	Change from baseline	37	1.35 ± 27.77	43	-3.09 ± 22.61	0.4325 a
	p-value c		0.7689		0.3748
Triglyceride (mg/dl)	Baseline	37	219.43 ± 132.92	43	173.28 ± 99.89	0.1060 b
	6 weeks	37	192.59 ± 134.18	43	180.09 ± 103.37
	Change from baseline	37	-26.84 ± 165.13	43	6.81 ± 98.78	0.0667 b
	p-valued		0.1090		0.4354
	12 weeks	36 e	176.56 ± 130.69	43	173.53 ± 88.06
	Change from baseline	36 e	-36.83 ± 161.27	43	0.26 ± 86.30	0.0251 b
	p-value d		0.0158		0.6696

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

^acompared with the placebo group (two sample t-test).

^bcompared with the placebo group (Wilcoxon rank sum test).

^ccomparisons within groups (paired t-test).

^dcomparisons within groups (Wilcoxon signed rank test).

^eexcluded from analysis since a value (2,332) deviated abnormally from the distribution of the test group (02-R044).